This company listing is no longer active
LCIN.Q Stock Overview
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lannett Company, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$3.72 |
| 52 Week Low | US$0.01 |
| Beta | 0.94 |
| 1 Month Change | 48.25% |
| 3 Month Change | -98.21% |
| 1 Year Change | -98.68% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.41% |
Recent News & Updates
Recent updates
Lannett announces 1-for-4 reverse stock split
Jan 25Lannett gains on patent deal for biosimilar insulin device
Nov 07Lannett gets FDA approval to manufacture Numbrino® at Seymour plant
Oct 21Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's Estimates
Sep 01
Lannett GAAP EPS of -$2.30, revenue of $74.19M
Aug 24Lannett: A Self-Inflicted Crisis
Feb 22Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue Forecasts
Feb 05A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)
Nov 05Is Lannett Company (NYSE:LCI) A Risky Investment?
Jun 20Lannett down 5.5%, SVC gains 5.7% as S&P 500 makes room for Organon
May 27Is Lannett Company (NYSE:LCI) A Risky Investment?
Mar 18Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)
Feb 11
Lannett shares slide on 2021 forecast cut, QF2 topline fall
Feb 04What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 15Is Lannett Company (NYSE:LCI) Using Too Much Debt?
Dec 11Lannett pays off remaining $42M in outstanding loans
Nov 30Lannett launches authorized generic of Tirosint
Nov 03Shareholder Returns
| LCIN.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.7% | -2.2% | -3.7% |
| 1Y | -98.7% | 11.6% | 20.5% |
Return vs Industry: LCIN.Q underperformed the US Pharmaceuticals industry which returned 4% over the past year.
Return vs Market: LCIN.Q underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| LCIN.Q volatility | |
|---|---|
| LCIN.Q Average Weekly Movement | 50.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LCIN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: LCIN.Q's weekly volatility has increased from 28% to 51% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1942 | 564 | Tim Crew | www.lannett.com |
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications.
Lannett Company, Inc. Fundamentals Summary
| LCIN.Q fundamental statistics | |
|---|---|
| Market cap | US$319.24k |
| Earnings (TTM) | -US$259.09m |
| Revenue (TTM) | US$310.67m |
0.0x
P/S Ratio0.0x
P/E RatioIs LCIN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCIN.Q income statement (TTM) | |
|---|---|
| Revenue | US$310.67m |
| Cost of Revenue | US$254.66m |
| Gross Profit | US$56.01m |
| Other Expenses | US$315.10m |
| Earnings | -US$259.09m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.06 |
| Gross Margin | 18.03% |
| Net Profit Margin | -83.40% |
| Debt/Equity Ratio | -152.4% |
How did LCIN.Q perform over the long term?
See historical performance and comparison